Applied NeuroSolutions inks drug pact with Lilly

Applied NeuroSolutions has inked a development deal with Eli Lilly for new drugs to treat Alzheimer's. Applied NeuroSolutions gains $2 million up front along with research funds. And it stands to earn between $10 million and $20 million for each new therapy that is developed. Applied NeuroSolutions has been investigating the proteins that gather on neurons in Alzheimer's cases.

- see this release on the development deal

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.